AGM Statement

Dechra Pharmaceuticals PLC
21 October 2004



Issued By Citigate Dewe Rogerson, Birmingham
Date Thursday, 21 October 2004
                                                               Immediate Release

                           Dechra Pharmaceuticals PLC
                             Annual General Meeting

At the Annual General Meeting held today (21 October), Michael Redmond, Chairman
told shareholders:

'The new financial year has started very strongly with Group sales and profit
for the first quarter ended 30 September 2004 ahead of both our internal budgets
and the comparable period last year.

As planned, following the full EU licence gained through the mutual recognition
procedure, Felimazole(R) was launched in the French and German markets earlier
this month; we have been encouraged by the initial interest in the product. Our
European marketing partner, Janssen Animal Health, will also launch Felimazole
(R) in other European territories during 2005.

Additionally we have achieved further progress on Vetoryl(R). We have been
granted the authority to market our low dose (30mg strength) for small dog
breeds within the UK. Our project to licence Vetoryl(R) in the USA continues on
track; within this current financial year we expect to have filed all parts of
the dossier with the FDA for further guidance prior to licence approval.

In the 2004 Annual Report, we indicated that we were at an advanced stage in
appointing a US national to head up our American marketing. I am pleased to
announce that on 1 November 2004, Michael Eldred joins the Group as President of
Dechra Veterinary Products, our fledgling US operation. Mike has extensive
experience in the animal health sector, having held senior positions at several
leading veterinary pharmaceutical companies including Virbac Corporation and
Fort Dodge Animal Health.

I look forward to updating shareholders further on our progress at the time of
our interim results in March 2005.'

All resolutions were duly passed.




Enquiries:
Ian Page, Chief Executive
Simon Evans, Group Finance Director                   Fiona Tooley, Director
Dechra(R) Pharmaceuticals PLC                         Citigate Dewe Rogerson
Mobile: [phone] (IP) or 07775 642220 (SE)        Today: 0121 455 8370
Thereafter: 01782 771100                              Mobile: [phone]
www.dechra.com
----------------




                      This information is provided by RNS
            The company news service from the London Stock Exchange